← Human Trials & Peer-Reviewed Studies
Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly
Plain-language guide to PMID 16003295 (2005): double-blind randomized controlled trial study of Octreotide and Somatostatin in 12 patients.
Key Facts
- PMID
- 16003295
- Journal
- Clinical pharmacology and therapeutics
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Ma P et al. (7 authors)
- DOI
- 10.1016/j.clpt.2005.04.003
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Octreotide and Somatostatin, published as a randomized controlled trial.
Acromegaly is a serious hormonal disorder resulting from a pituitary adenoma causing excess growth hormone (GH) production.
Somatostatin analogs such as octreotide have been the medical treatment of choice.
Who Took Part
According to the abstract, 12 patients were involved.
PubMed indexes the participants as adults and middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and crossover study.
Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.
As a double-blind Octreotide study, the assignments were hidden from both participants and investigators until the end.
In the crossover set-up each of the patients took both Octreotide and the comparison in turn, acting as their own control.
The PK properties of SOM230 and octreotide and the relationship of PK with GH were investigated by a nonlinear mixed-effects modeling analysis.
What Was Measured
PubMed files the paper under topics including Acromegaly, Age Factors, Algorithms, Circadian Rhythm, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic and Human Growth Hormone.
What This Means in Plain Language
The paper is a randomized, double-blind and crossover study of Octreotide and Somatostatin in 12 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2005 (Clinical pharmacology and therapeutics), a journal based in United States.
More context: the Octreotide compound page and the Somatostatin compound page, all human trials.
Our Notes on the Compounds
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.